U.S. Markets closed

Medtronic to Grow on Strong Fundamentals, High Costs a Woe

Zacks Equity Research
1 / 2

Stock Market News For Nov 16, 2018

Wall Street finished in the green reversing its five-day negative trend on Thursday following news that United States and China have ramped up their efforts to resolve lingering trade disputes

On Apr 3, we issued an updated research report on Medtronic plc MDT. While we are encouraged by the global acceptance of the company’s advanced therapies, its escalating costs and expenses raise concerns. The company has a Zacks Rank #3 (Hold).

On a positive note, we are upbeat about Medtronic’s recently-launched restructuring initiative called Enterprise Excellence plan, aimed at $3-billion annual growth run rate savings by the end of fiscal 2022. Per the company, this new program has been designed to increase its effectiveness and growth-related reinvestment ability along with a consistent boost to margin expansion and driving the EPS leverage.

Also, a gradually stabilizing movement witnessed in the global Cardiac Rhythm & Heart Failure (CRHF) market bodes well for further improvement in the coming quarters.

Medtronic PLC Price

Medtronic PLC Price | Medtronic PLC Quote


Meanwhile, at the end of third-quarter fiscal 2018, Medtronic noted that it has successfully met its $850 million Covidien synergy commitments in time. Significantly, this comes under one of the company’s four priorities, which is, ‘optimize’. Per this commitment, Medtronic has started to deliver $225-$250 million in cost synergies and $850 million in annual savings by the end of fiscal 2018.

On the flip side, shares of Medtronic have underperformed the broader industry over the past three months. The stock has lost 8% versus the broader industry’s 2.5% gain.

The company has been exposed to escalating costs and expenses, weighing heavily on its margins. Its reiteration of 2018 guidance despite a favorable foreign currency translation forecast dampens investors’ confidence in the stock.

Key Picks

A few better-ranked stocks in the broader medical sector are Bio-Rad Laboratories BIO, athenahealth, Inc. ATHN and Edwards Lifesciences Corporation EW.

Bio-Rad Laboratories sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. It has a long-term expected earnings growth rate of 20%.

athenahealth is a Zacks #1 Ranked player. It has a long-term expected earnings growth rate of 21.5%.

Edwards Lifesciences has a long-term expected earnings growth rate of 15.1% and a Zacks Rank #2 (Buy).

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
athenahealth, Inc. (ATHN) : Free Stock Analysis Report
Medtronic PLC (MDT) : Free Stock Analysis Report
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research